Skip to content

CBT-I for the Patients With Chronic Insomnia in China

A Pilot Study of CBT-I for the Patients With Chronic Insomnia in China

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07730593
Acronym
CBT-I
Enrollment
19
Registered
2026-07-28
Start date
2018-07-01
Completion date
2019-12-01
Last updated
2026-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CBTI Insomnia

Brief summary

Insomnia is one of major public health problems.This study aimed to assess benefits and problems of CBT-I for chronic insomnia based on the influence of Chinese tradition and culture.

Detailed description

Participants with chronic insomnia were enrolled to a 6 weeks CBT-I program . At baseline and follow-up to week 12, all patients were assessed using polysomnography (PSG), sleep diary and subjective scales.

Interventions

BEHAVIORALcognitive behavioral therapy for insomnia

CBT-I has been developed as a structured clinical practice, which integrates a constellation of treatment components, such as stimulus control, sleep restriction,relaxation therapy, cognitive therapy and sleep hygiene education

Sponsors

Peking University People's Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
37 Years to 76 Years
Healthy volunteers
No

Inclusion criteria

* were diagnosed as chronic insomnia based on the third edition of the International Classification of Sleep Disorders(ICSD-3) ; * agree to participate in this study and sign informed consent.

Exclusion criteria

* Patient Health Questionnaire(PHQ-9)\> 15 points; * hallucinations or taking antipsychotic medication at the time of evaluation; * Insomnia due to drug side effects, other illnesses or co-morbidities; * dementia according to 4th edition of the Diagnostic and Statistical Manual of Mental Disorders; * severe physical illness or severe abnormalities in heart, liver, kidney and thyroid function.

Design outcomes

Primary

MeasureTime frameDescription
Change of Polysomnography (PSG) parameters - TST6 weeks.total sleep time

Secondary

MeasureTime frameDescription
Change of Polysomnography (PSG) parameters-SOL6 weekssleep onset latency (SOL)
Change of Polysomnography (PSG) parameters-TIB6 weekstime in bed (TlB)
Change of Polysomnography (PSG) parameters-SE6 weekssleep efficiency(SE)
Change of Polysomnography (PSG) parameters-REM latency6 weeksRapid Eye Movement (REM)
Change of Polysomnography (PSG) parameters- Stage R6 weeks
Change of Polysomnography (PSG) parameters-Stage N16 weeks
Change of Polysomnography (PSG) parameters-Stage N26 weeks
Change of Polysomnography (PSG) parameters-Stage N36 weeks
Change of Polysomnography (PSG) parameters-Arousal6 weeks
Change of Polysomnography (PSG) parameters-SpO2 mean6 weeks
Change of Polysomnography (PSG) parameters-AHI6 weeksapnea-hypopnea index (AHI)
Change of sleep diary parameters-SOL6 weekssleep onset latency (SOL)
Change of sleep diary parameters-TST6 weekstotal sleep time (TST)
Change of sleep diary parameters-TIB6 weekstime in bed (TlB)
Change of sleep diary parameters-SE6 weekssleep efficiency(SE)
Change of sleep diary parameters-NAD6 weeksnumber of awakenings during the night (NAD)
Change of sleep diary parameters-WASO6 weekswake time after sleep onset (WASO)
Change of lSl12 weeksinsomnia severity index. The total score ranges from 0 to 28, with higher scores indicating more severe insomnia symptoms. A decrease from baseline indicates improvement.
Change of PSQl12 weeksPittsburg sleep quality index. The global score ranges from 0 to 21, with higher scores indicating poorer sleep quality. A decrease from baseline indicates improvement.
Change of SAS12 weeksSelf-Rating Anxiety Scale. The index score ranges from 20 to 80, with higher scores indicating more severe anxiety symptoms. A decrease from baseline indicates improvement.
Change of SDS12 weeksSelf-rating depression scale. The index score ranges from 20 to 80, with higher scores indicating more severe depressive symptoms. A decrease from baseline indicates improvement.

Countries

China

Contacts

STUDY_CHAIRhuailian guo, Dr,

Peking University People's Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 29, 2026